Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CanSino Inhaled COVID-19 Vaccine Approved in China as Booster

publication date: Sep 9, 2022

Tianjin CanSino Biologics reported that an aerosolized version of its COVID-19 vaccine has been approved for China use as a COVID booster vaccine. CanSino pointed to preliminary study results showing the inhaled vaccine provided immunity after a single dose, but the company did not release detailed efficacy results.  The company’s COVID-19 vaccine, which is delivered by an adenovirus Type 5 vector, is 65% effective at preventing all symptomatic COVID-19 disease and 90% effective at preventing severe disease. CanSino partnered the COVID vaccine with the Beijing Institute of Biotechnology, Academy of Military Medical Sciences. More details....

Stock Symbols: (SHA: 688185; HK: 06185)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022